nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

18.02.2019 | Original Article – Cancer Research

Clinical impact of circulating LAPTM4B-35 in pancreatic ductal adenocarcinoma

verfasst von: Zixuan Yang, Norbert Senninger, Isabelle Flammang, Qifa Ye, Sameer A. Dhayat

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

LAPTM4B is upregulated in a wide range of cancers associated with poor prognosis. However, the clinical impact of LAPTM4B as diagnostic and prognostic marker in pancreatic ductal adenocarcinoma (PDAC) remains unknown. Thus, the aim of the present study was to investigate the expression of LAPTM4B as circulating marker in PDAC.

Methods

Expression analysis of LAPTM4B-35 in pancreatic tissue and preoperative blood serum samples of 169 patients with PDAC UICC Stages I–IV (n = 98), chronic pancreatitis (n = 41), and healthy controls (n = 30) by immunohistochemistry, Western blot, and ELISA. Descriptive and explorative statistical analyses of LAPTM4B-35’s potential as diagnostic and prognostic marker in PDAC.

Results

Expression of LAPTM4B-35 was significantly increased in tumor tissue and corresponding blood serum samples of patients with PDAC (each p < 0.001) and it could well discriminate PDAC from healthy controls and chronic pancreatitis (p < 0.001; p = 0.0037). LAPTM4B-35 in combination with CA.19-9 outperforms the diagnostic accuracy with an AUC of 0.903 (p < 0.001), sensitivity of 82%, and specificity of 92%. Kaplan–Meier survival analysis revealed an improved overall survival in PDAC UICC I–IV with low expression of circulating LAPTM4B-35 (17 versus 10 months, p = 0.039) as well as an improved relapse-free survival in curatively treated PDAC UICC I–III (16 versus 10 months; p = 0.037). Multivariate overall and recurrence-free survival analyses identified LAPTM4B-35 as favorable prognostic factor in PDAC patients (HR 2.73, p = 0.021; HR 3.29, p = 0.003).

Conclusion

LAPTM4B-35 is significantly deregulated in PDAC with high diagnostic and prognostic impact as circulating tumor marker.

Nur mit Berechtigung zugänglich

Amin MB et al (2017) The Eighth Edition AJCC Cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 67:93–99. https://doi.org/10.3322/caac.21388 CrossRef

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492 CrossRef

Cheng XJ et al (2015) LAPTM4B-35, a cancer-related gene, is associated with poor prognosis in TNM Stages I–III gastric cancer patients. Plos One. https://doi.org/10.1371/journal.pone.0121559 CrossRefPubMedPubMedCentral

Dhayat SA, Abdeen B, Kohler G, Senninger N, Haier J, Mardin WA (2015) MicroRNA-100 and microRNA-21 as markers of survival and chemotherapy response in pancreatic ductal adenocarcinoma UICC stage II. Clin Epigenet 7:132. https://doi.org/10.1186/s13148-015-0166-1 CrossRef

Hidalgo M (2010) Pancreatic cancer. N Engl J Med 362:1605–1617. https://doi.org/10.1056/NEJMra0901557 CrossRefPubMed

Kamisawa T, Wood LD, Itoi T, Takaori K (2016) Pancreatic cancer. Lancet 388:73–85. https://doi.org/10.1016/S0140-6736(16)00141-0 CrossRefPubMed

Kang Y, Yin MZ, Jiang W, Zhang HY, Xia BR, Xue YW, Huang YN (2012) Overexpression of LAPTM4B-35 is associated with poor prognosis in colorectal carcinoma. Am J Surg 204:677–683. https://doi.org/10.1016/j.amjsurg.2012.02.003 CrossRefPubMed

Kasper G et al (2005) The human LAPTM4b transcript is upregulated in various types of solid tumours and seems to play a dual functional role during tumour progression. Cancer Lett 224:93–103. https://doi.org/10.1016/j.canlet.2004.10.004 CrossRefPubMed

Li L et al (2010) LAPTM4B: a novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling. Oncogene 29:5785–5795. https://doi.org/10.1038/onc.2010.303 CrossRefPubMed

Lim JE, Chien MW, Earle CC (2003) Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg 237:74–85. https://doi.org/10.1097/01.SLA.0000041266.10047.38 CrossRefPubMedPubMedCentral

Liu J, Zhou R, Zhang N, Rui J, Jin C (2000) Biological function of a novel gene overexpressed in human hepatocellular carcinoma. Chin Med J (Engl) 113:881–885

Liu XR, Xiong FX, Wei XH, Yang H, Zhou RL (2009) LAPTM4B-35, a novel tetratransmembrane protein and its PPRP motif play critical roles in proliferation and metastatic potential of hepatocellular carcinoma cells. Cancer Sci 100:2335–2340. https://doi.org/10.1111/j.1349-7006.2009.01346.x CrossRefPubMed

Meng FL, Yin MZ, Song HT, Yang H, Lou G, Zhou RL (2010) LAPTM4B-35 overexpression is an independent prognostic marker in endometrial carcinoma. Int J Gynecol Cancer 20:745–750. https://doi.org/10.1111/IGC.0b013e3181e02f90 CrossRefPubMed

Meng Y et al (2016) LAPTM4B: an oncogene in various solid tumors and its functions. Oncogene 35:6359–6365. https://doi.org/10.1038/onc.2016.189 CrossRefPubMedPubMedCentral

Neuzillet C et al (2015) State of the art and future directions of pancreatic ductal adenocarcinoma therapy. Pharmacol Ther 155:80–104. https://doi.org/10.1016/j.pharmthera.2015.08.006 CrossRefPubMed

Qiao M, Hu GH (2015) Lysosome-associated protein transmembrane-4 beta-35 is a novel independent prognostic factor in small cell lung cancer. Tumor Biol 36:7493–7499. https://doi.org/10.1007/s13277-015-3467-2 CrossRef

Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM (2014) Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United. States Cancer Res 74:2913–2921. https://doi.org/10.1158/0008-5472.CAN-14-0155 CrossRefPubMed

Shao GZ et al (2003) Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma. Oncogene 22:5060–5069. https://doi.org/10.1038/sj.onc.1206832 CrossRefPubMed

Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68:7–30. https://doi.org/10.3322/caac.21442 CrossRefPubMed

Tan XJ, Sun Y, Thapa N, Liao YH, Hedman AC, Anderson RA (2015) LAPTM4B is a PtdIns(4,5)P-2 effector that regulates EGFR signaling, lysosomal sorting, and degradation. Embo J 34:475–490. https://doi.org/10.15252/embj.201489425 CrossRefPubMedPubMedCentral

Vergarajauregui S, Martina JA, Puertollano R (2011) LAPTMs regulate lysosomal function and interact with mucolipin 1: new clues for understanding mucolipidosis type IV. J Cell Sci 124:459–468. https://doi.org/10.1242/jcs.076240 CrossRefPubMedPubMedCentral

Wang B, Wang S, Liang G, Xu J, Zhou R, Zhang Q (2017) Association of lysosomal protein transmembrane 4 beta gene polymorphism with pancreatic carcinoma susceptibility in the Chinese population. Tumour Biol 39:1010428317705518. https://doi.org/10.1177/1010428317705518 CrossRefPubMed

Xia LZ et al (2015) The relationship between LAPTM4B polymorphisms and cancer risk in Chinese Han population: a meta-analysis. Springerplus. https://doi.org/10.1186/s40064-015-0941-7 CrossRefPubMedPubMedCentral

Xiao M, Jia SS, Wang HB, Wang JS, Huang YX, Li ZG (2013) Overexpression of LAPTM4B: an independent prognostic marker in breast cancer. J Cancer Res Clin 139:661–667. https://doi.org/10.1007/s00432-012-1368-y CrossRef

Yang H et al (2010a) LAPTM4B-35 is a novel prognostic factor of hepatocellular carcinoma. J Surg Oncol 101:363–369. https://doi.org/10.1002/jso.21489 CrossRefPubMed

Yang H, Xiong FX, Wei XH, Yang Y, McNutt MA, Zhou RL (2010b) Overexpression of LAPTM4B-35 promotes growth and metastasis of hepatocellular carcinoma in vitro and in vivo. Cancer Lett 294:236–244. https://doi.org/10.1016/j.canlet.2010.02.006 CrossRefPubMed

Yin MZ et al (2011) Over-expression of LAPTM4B is associated with poor prognosis and chemotherapy resistance in stages III and IV epithelial ovarian cancer. J Surg Oncol 104:29–36. https://doi.org/10.1002/jso.21912 CrossRefPubMed

Zhang G, Liang Y, Huang Y, Chen Y, Zhou R (2012) Elevated lysosome-associated protein transmembrane-4beta-35 is an independent prognostic marker in pancreatic carcinoma. J Int Med Res 40:1275–1283. https://doi.org/10.1177/147323001204000406 CrossRefPubMed

Zhang HT et al (2014) Overexpression of LAPTM4B-35: a novel marker of poor prognosis of prostate cancer. Plos One. https://doi.org/10.1371/journal.pone.0091069 CrossRefPubMedPubMedCentral

Zhang X, Shi S, Zhang B, Ni Q, Yu X, Xu J (2018) Circulating biomarkers for early diagnosis of pancreatic cancer: facts and hopes. Am J Cancer Res 8:332–353PubMedPubMedCentral

Zhou L et al (2008) Expression of LAPTM4B-35: A novel marker of progression, invasiveness and poor prognosis of extrahepatic cholanglocarcinoma. Cancer Lett 264:209–217. https://doi.org/10.1016/j.canlet.2008.01.025 CrossRefPubMed

Zhou L, He XD, Yu JC, Zhou RL, Shan Y, Rui JA (2011) Overexpression of LAPTM4B-35 attenuates epirubucin-induced apoptosis of gallbladder carcinoma GBC-SD cells. Surgery 150:25–31. https://doi.org/10.1016/j.surg.2010.12.010 CrossRefPubMed

Titel: Clinical impact of circulating LAPTM4B-35 in pancreatic ductal adenocarcinoma
verfasst von: Zixuan Yang
Norbert Senninger
Isabelle Flammang
Qifa Ye
Sameer A. Dhayat
Publikationsdatum: 18.02.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 5/2019
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-019-02863-w

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Clinical impact of circulating LAPTM4B-35 in pancreatic ductal adenocarcinoma

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2019

TRPM2 mediates distruption of autophagy machinery and correlates with the grade level in prostate cancer

The application of ApcMin/+ mouse model in colorectal tumor researches

CIK cell-based delivery of recombinant adenovirus KGHV500 carrying the anti-p21Ras scFv gene enhances the anti-tumor effect and safety in lung cancer

Impact of nodal status and treatment strategy on overall survival in advanced stage cervical cancer

Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer

CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie